Shareholders Equity: The sum of preferred and common equity items.
ZyVersa Therapeutics, Inc. (ZVSA) had Shareholders Equity of $-12.39M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-24.95M |
|
-- |
|
-- |
|
$25.49M |
|
$-25.49M |
|
$-0.31M |
|
$-25.80M |
|
$-25.80M |
|
$-24.95M |
|
$-24.95M |
|
$-24.95M |
|
$-24.95M |
|
$-25.49M |
|
$-25.49M |
|
5.96M |
|
5.96M |
|
$-4.18 |
|
$-4.18 |
|
| Balance Sheet Financials | |
$0.35M |
|
-- |
|
-- |
|
$0.35M |
|
$12.73M |
|
-- |
|
-- |
|
$12.73M |
|
$-12.39M |
|
$-12.39M |
|
|
Shareholders Equity |
$-12.39M |
8.10M |
|
| Cash Flow Statement Financials | |
$-5.11M |
|
-- |
|
$3.69M |
|
$1.53M |
|
$0.10M |
|
$-1.43M |
|
$0.22M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.03 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-5.11M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
201.44% |
|
201.44% |
|
-7172.26% |
|
201.44% |
|
$-1.53 |
|
$-0.86 |
|
$-0.86 |
|